ClinicalTrials.gg
CompletedNCT01431495(CAPP)Updated Sep 9, 2011

Clinical Assessment of Pidogrel® Versus Plavix® (CAPP)

A Phase 4 interventional study of Pidogrel and Plavix in Coronary Disease, sponsored by Les Laboratoires des Médicaments Stériles. Completed at 1 site in Tunisia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-09-09.

Sponsored by Les Laboratoires des Médicaments Stériles · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
219
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing clopidogrel in Coronary Disease — none open to participants now, none under way, none of them phase 3. Clopidogrel · Coronary Disease.

Enrollment
11th of 17
219 · median 306
Started
2010
with 1 other
Phase 4
15 of 17
none open now
Registered
10th of 17
by date
Lead sponsor
1 of 17
Les Laboratoires des Médicaments Stériles

Among the 17 studies testing clopidogrel in Coronary Disease, this one is the 11th largest by enrollment, is one of 2 that started in 2010, is one of 15 in phase 4, and was the 10th registered.

Coronary Disease

1,521 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

None of the 17 studies testing clopidogrel in Coronary Disease is open now. The open studies under Coronary Disease, anywhere →

About clopidogrel

Clopidogrel: first FDA approval 1997 (PLAVIX), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 105 Coronary Disease studies recruiting now, 63 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing clopidogrel in Coronary Disease as a file.
02

Study summary

This study aims to demonstrate non-inferiority of Pidogrel ® compared to Plavix ® in patients with coronary disease:

  • Primary Outcome Measures: measure of platelet reactivity by VerifyNow assay after 600 mg loading dose or after the last maintenance dose (75 mg).
  • Secondary Outcome Measures: Time to first occurrence of major cardio-vascular events (MACE).
  • Safety Criteria: severe bleeding (GUSTO scale).
Read the detailed description

after randomization of patients in both groups (Plavix or Pidogrel), the measure of platelet activity by the VerifyNow assay, 4 to 12 hours after the loading dose of 600mg or after the last dose of clopidogrel for patients on maintenance dose. The VerifyNow assay will determine: - The PRU:-P2Y12 Reaction Units-

-% Of platelet inhibition It will be considered low responder or clopidogrel resistant patient with PRU> 235 or %inhibition \<15%.

Monitoring of patients included in the study will take place over a period of 12 months, MACE will be notified and dated. MACE criteria are: angina, myocardial infarction, coronary angioplasty, coronary artery bypass graft, and stroke.

Each hemorrhagic event will be notified and classified according to the GUSTO scale.

03

Conditions studied

  • Coronary Disease

Keywords

  • platelet agregation
  • clopidogrel
  • major adverse cardiac events (MACE)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female,
  • Old (e) over 20 years
  • Patients hospitalized for acute coronary syndrome (Whatever the T and troponin)
  • Patients with proven coronary candidates for treatment with clopidogrel (who received a loading dose of 600mg over 2 hours and treated with 75mg / d of clopidogrel for longer than 7 days)

Exclusion criteria

Exclusion Criteria:

  • Patients unwilling.
  • Patient participating in another study.
  • Patients with cardiogenic shock
  • Patient on anti GpIIbIIIa or stopped less than 72 hours before the test aggregability
  • Patients scheduled for surgery in less than 6 months.
  • Patients candidates for coronary angioplasty
  • Patients who underwent TAC + / - bare stent fewer than 30 days.
  • Patients who underwent stenting with ATC active there is less than 12 months.
  • ischemic stroke older than 6 weeks.
  • History of hemorrhagic stroke (any time)
  • Patients on warfarin or candidates
  • Patients with a different anti ADP (ticlopidine, prasugrel)
  • Patients with indication for clopidogrel-cons (side effects, bleeding ...)
  • Thrombocytopenia \<100000/mm3
  • anemia (Ht \<30%)
  • Thrombocythaemia (Ht> 52%)
  • Patients seeking treatment for an elective forms of Clopidogrel.
  • Pregnancy
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
219 participants (actual)

Study arms

  • Active comparator
    plavix

    patient treated by the princeps

    Drug: Plavix

  • Active comparator
    Pidogrel

    patient treated by Pidogrel

    Drug: Pidogrel

Interventions

  • Pidogrel(R)75 mg/day for period ranging from 1 to 6 months.

  • DrugPlavix

    Plavix(R) 75 mg/day for period ranging from 1 to 6 months.

06

What researchers measure

Primary outcomes

  1. - study the respective effects of Pidogrel ® and Plavix ® on platelet aggregation through the test VerifyNow ® - Time to first occurrence of post-randomization major adverse cardiac events (MACE)

    Time frame: 06 months

07

Study locations

1 site
  • cardiology department, hospital La RABTA
    Tunis, Tunis BAB SOUIKA 1007, Tunisia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of Jun 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2011
First posted
Sep 9, 2011
Start
Apr 2010
Primary completionActual
Jun 2011
CompletionActual
Jul 2011
Last update
Sep 9, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01431495
Lead sponsor
Les Laboratoires des Médicaments Stériles
Responsible party
Sponsor
First posted
Sep 9, 2011
Start date
Apr 2010
Primary completion
Jun 2011
Completion
Jul 2011
Last update
Sep 9, 2011

Study contacts

Rachid MECHMECHE, MD
study chair · hospital La RABTA

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clopidogrel

Start the discussion